Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC)
Received Date: May 16, 2018 / Accepted Date: Jun 14, 2018 / Published Date: Jun 16, 2018
Nivolumab, a humanized IgG4 programmed death-1 (PD-1) inhibitor antibody, is approved in Italy for advanced non small cell lung cancer (NSCLC), for advanced melanoma in association with ipilimumab, in second line renal cell carcinoma (RCC), in Hodgkin lymphoma relapsed after autologous stem cell transplantation and treatment with brentuximab vedotin, in head and neck squamous cell carcinoma progressed after platinum therapy and in locally advanced urothelial carcinoma unresectable or metastatic after failure of previous platinum therapy. Its immunogenic potential is well known, with described autoimmune-like syndromes, but no clear association is evident for hemolytic anemia. We report case of a 68-year-old man who developed hemolytic anemia after 28 cycles of treatment for advanced Squamous Cell Lung Cancer (SSC).
Keywords: Nivolumab; Hemolitic anemia; Squamous cell lung cancer; Hodgkin lymphoma; Anticancer effect; Carcinoma
Citation: Scotti V, Maragna V, Meacci F, Teriaca MA, Topulli J, et al. (2018) Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC). J Cancer Sci Ther 10:143-144. Doi: 10.4172/1948-5956.1000532
Copyright: © 2018 Scotti V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
April 20-21, 2020 Berlin, Germany
- Total views: 1789
- [From(publication date): 0-2018 - Dec 09, 2019]
- Breakdown by view type
- HTML page views: 1741
- PDF downloads: 48